Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT03293030
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a single-arm, open-label study to examine the effect of dupilumab on the immunologic and genetic environment within atopic dermatitis skin lesions.

Key Dates

Start date
Oct 22, 2018
Status verified
Oct 2025
Primary completion
Feb 23, 2023
Completion
Feb 23, 2023

Study Design

Enrollment
17 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Dupilumab treatment
    15 subjects will receive dupilumab for a treatment period of 52 weeks (i.e. last injection on week 50). All subjects will undergo skin biopsies for molecular profiling.

Primary Outcome Measure

Percent Change in CD4+ T Effector Cells Expressing IL4 in Dupilumab-treated Subjects at Week 12 vs Week 0 [ Time Frame: 12 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
UCSF Psoriasis and Skin Treatment CenterSan FranciscoCalifornia94118-

Find similar trials in San Francisco, CA

By condition
Atopic dermatitis / eczema
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
UCSF Psoriasis and Skin Treatment Center· San Francisco, CA

Related Studies